title: Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji.
abstract: Previous studies from our laboratory indicated that human NK activity against HSV-infected fibroblasts (HSV-Fs) but not K562 targets was sensitive to treatment with anti-HLA-DR plus C. In the current study, we have selected Leu-11a+ (CD-16) cells by fluorescence activated cell sorting and found that although Leu-11a enriched populations lysed K562 targets in 14-h 51Cr-release assays, they were unable to kill HSV-Fs targets unless a Leu-11a-depleted population was added back to the effectors or unless known activators of NK cells (IFN-alpha or IL-2) were added to the assays. In contrast, Leu-11a-enriched populations were able to mediate ADCC against HSV-Fs in the presence of sera from HSV-seropositive individuals without the requirement for accessory cells. We have begun preliminary characterization of the accessory cells which allow lysis of HSV-Fs by NK cells: they are HLA-DR+ cells which enrich in the light density fractions of Metrizamide density gradients. They need be present in very small numbers for lysis to take place and are not MHC restricted in that heterologous add-backs between anti-HLA-DR plus C and anti-Leu-11b plus C-treated populations are capable of target cell lysis at levels similar to those achieved with the autologous add-backs. Further, the levels of lysis in heterologous add-back experiments reflected the lytic potential of the effector rather than the accessory cell donor. Finally, although the requirement for accessory cells for NK lysis has been demonstrated for fibroblasts infected with HSV-1, CMV, and VZV, lysis of HSV-infected Raji lymphoblastoid cells is relatively accessory-cell independent, indicating that the requirement for accessory cells for lysis by NK cells is not a property of all herpesvirus-infected targets.
authors.affiliation: Department of Pathology, University of Medicine and Dentistry of New Jersey, Newark 07103.
authors.forename: P
authors.initials: P
authors.lastname: Fitzgerald-Bocarsly
authors.forename: M
authors.initials: M
authors.lastname: Feldman
authors.forename: S
authors.initials: S
authors.lastname: Curl
authors.forename: J
authors.initials: J
authors.lastname: Schnell
authors.forename: T
authors.initials: T
authors.lastname: Denny
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000920:Antibody-Dependent Cell Cytotoxicity; D000938:Antigen-Presenting Cells / Q000145:classification / Q000276:immunology*; D000943:Antigens, Differentiation; D002460:Cell Line; D002469:Cell Separation; D003165:Complement System Proteins / Q000502:physiology; D005347:Fibroblasts / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology; D006561:Herpes Simplex / Q000276:immunology*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000145:classification / Q000276:immunology*; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology; D010641:Phenotype; D011961:Receptors, Fc; D017452:Receptors, IgG; D011994:Recombinant Proteins
chemical_list: D000276:Adjuvants, Immunologic; D000943:Antigens, Differentiation; D006684:HLA-DR Antigens; D007370:Interferon Type I; D007376:Interleukin-2; D011961:Receptors, Fc; D017452:Receptors, IgG; D011994:Recombinant Proteins; D003165:Complement System Proteins